Theracule Sarl is a personalized drug discovery and orphan drug development company for genetic forms of epilepsy and neurodegenerative diseases.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Theracule has developed an in vivo drug discovery platform using zebrafish and mouse models for orphan drug development. Initial efforts focus on developing drugs for the third of epilepsy patients who are resistant to existing epilepsy drugs. Theracules pipeline starts by identifying common gene mutations among PRE patients for which genetically equivalent zebrafish and mouse models are created. These zebrafish, which display epilepsy-like phenotypes, are screened against thousands of chemical compounds.